Investors Research Corp’s Apexigen, Inc. Common Stock APGN Stock Holding History

Investors Research Corp’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15	Closed	–	–	1175
2022 Q1	$0	Hold	15	–	–	﹤0.01%	1112
2021 Q4	$0	Hold	15	–	–	﹤0.01%	1062
2021 Q3	$0	Hold	15	–	–	﹤0.01%	1047
2021 Q2	$0	Hold	15	–	–	﹤0.01%	1027
2021 Q1	$0	Buy	+15	New	+$150	﹤0.01%	1093

Other funds holding APGN

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Investors Research Corp's APGN Position: Q2 2022 in Review

Investors Research Corp sold out of Apexigen, Inc. Common Stock (APGN) in Q2 2022, closing a stake of 15 shares.

Investors Research Corp first reported a position in APGN in Q1 2021 and held it in 5 quarters. The position peaked at $0 in Q1 2022. 27 funds tracked by Wall St. Rank hold APGN as of Q2 2022.

Investors Research Corp reported no remaining Apexigen, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Investors Research Corp sold 15 Apexigen, Inc. Common Stock shares in Q2 2022.
Investors Research Corp first reported a position in Apexigen, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Investors Research Corp's Apexigen, Inc. Common Stock position peaked at $0 in Q1 2022.
27 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q2 2022.

Based on Investors Research Corp's 13F filing for Q2 2022, filed 21 Jul 2022.